Biotechnology

Roivant Sciences

Roivant Sciences to Release FY2026 Q4 Earnings on May 20 Pre-Market EST, Forecast Revenue USD 3.913 M, EPS USD -0.3412

Roivant Sciences CEO Sells $8.4 Million in Common Stock

Roivant Initiates 2b/3 Phase Clinical Trial for Brepocitinib in Treatment of LPP Alopecia

Roivant's brepocitinib succeeds in phase III clinical trial for dermatomyositis

Roivant Sciences' stock rises following settlement and repurchase program

Frank Torti Sells 3 Million Shares of Roivant Sciences Ltd.

Roivant Sciences Director Daniel Allen Gold Disposes of Common Stock

Roivant Sciences released FY2026 Q3 earnings on February 6 Pre-Market (EST), actual revenue USD 1.999 M (forecast USD 6.139 M), actual EPS USD -0.3815 (forecast USD -0.31)

Roivant Sciences released FY2026 9 Months Earnings on February 6 Pre-Market EST, with actual revenue of USD 5.74 M and EPS of USD -0.8815

Roivant Sciences to Release FY2026 Q3 Earnings on February 6, 2026 Pre-Market EST, Forecast Revenue USD 6.139M, EPS USD -0.31

Roivant Sciences Ltd. CEO Eric Venker Sells Company Shares

Roivant Sciences insiders sold $28.9 million worth of shares

Roivant Sciences Executives Sell Large Amounts of Stock

Roivant Sciences Ltd's 2026 EPS forecast revised upward

Roivant Sciences CEO sells stocks

QVT Financial LP Disposes of Roivant Sciences Ltd. Common Stock

Roivant Sciences Ltd CEO Reports Disposition of Common Stock

Roivant Sciences Ltd. shareholder Vivek Ramaswamy reports sale of common stock

Goldman Sachs Raises Roivant Sciences Price Target to $33

Roivant Sciences Ltd. Acquires Immunovant Inc.

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Pinned News

置顶新闻

Roivant Sciences Ltd. FY 2026: Revenue $8.26M, EPS ($0.54) — 10-K Summary

Earning Release Date

财报预告

FY2026 Q4 Earning Release Today 2026.05.20 (EST) Pre-Market

ROIV

LABU

ARKG

SBIO

Roivant Sciences Ltd. reported FY 2026 results with revenue of $8.26M, a 71.6% decline from $29.05M, and a net loss of $299.77M, widening from $171.98M. Diluted EPS fell to ($0.54). The revenue drop was attributed to lower license income and increased R&D spending, which rose to $681.8M. The company recognized a $770.2M litigation settlement gain and focused on core clinical priorities following strategic divestitures.

TradingView

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

VG Health

Proshares Ultra Nasdaq Biotech

iShares Global Healthcare

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

iShares Biotechnology ETF

VanEck Biotech ETF

SPDR S&P Biotech

Roivant Sciences shares are trading higher after the company reported better-than-expected Q4 adjusted EPS results.

benzinga_article

Earnings Watch

Roivant Sciences | 10-K: FY2026 Revenue Misses Estimate at USD 8.26 M

Roivant Sciences | 8-K: FY2026 Revenue Misses Estimate at USD 8.26 M

Roivant reported a Q4 net income of $302.99 million, a turnaround from a loss last year, driven by a $770.24 million litigation settlement gain. However, revenue fell 66.71% to $2.52 million, while R&D expenses rose 36.98% to $198.95 million. The company holds $4.3 billion in cash and equivalents, supporting its path to profitability. Roivant anticipates launching brepocitinib in September 2026, with key clinical data expected later in the year.

PUBT

Moderna

Roivant Q4 swings to profit of $355.7 million; revenue falls to $2.52 million

Roivant Sciences Ltd.'s stock price target has been raised to $36.23, indicating a potential upside of 28%. The average target increased from $35.71, with estimates ranging from $29.5 to $41 per share. The consensus rating remains 'Buy' from 13 analysts, including 12 Buys and 1 Hold.

Factset Research

Roivant Sciences Ltd. Stock 12‑Month Price Target Raised to $36.23, Implies 28% Upside

On May 20, 2026, several companies are set to report earnings, including ADI, TJX, LOW, TGT, ROIV, HAS, GDS, and VFC. ADI expects $2.89 EPS, a 56.22% increase; TJX forecasts $1.01 EPS, up 9.78%; LOW anticipates $2.96 EPS, a 1.37% rise; TGT projects $1.37 EPS, a 5.38% increase. ROIV expects a loss of $-0.38 EPS, down 22.58%. HAS forecasts $1.12 EPS, up 7.69%; GDS expects $1.06 EPS, a 120.83% increase; VFC anticipates $-0.02 EPS, up 84.62%.

nasdaq

Hasbro

Target

Analog Devices

Lowes

ZIM Integrated Shipping Services

Kanzhun

BOSS ZHIPIN-W

Pre-Market Earnings Report for May 20, 2026 :  ADI, TJX, LOW, TGT, ROIV, HAS, GDS, VFC, BZ, IMVT, ZIM, ARCO

510660

ROIS CDMO has acquired a commercial injectable manufacturing facility in Phoenix, Arizona, marking a significant step in its evolution as a global Contract Development and Manufacturing Organisation (CDMO). This expansion enhances ROIS's capabilities in developing and manufacturing injectable medicines, particularly for rare diseases, obesity, and cancer. The company aims to better support its global customers and reinforce its commitment to innovation and quality in injectable drug development. ROIS is recognized for its high-capacity manufacturing and has received approvals from major regulatory bodies.

Fidelity

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund CSI 300 Health Care ETF

Guotai CSI Bio-medicine ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Proshares UltraShort Nasdaq Biotech

ROIS establishes itself as Global CDMO with US Expansion

On April 22, 2026, Eric Venker, President and CEO of Immunovant, sold 200,000 shares of Roivant Sciences (ROIV) for $5.9 million, indicating a significant insider move. Roivant's stock has risen approximately 190% over the past year, driven by positive data from its drug brepocitinib. Analysts from Piper Sandler have initiated coverage, highlighting the drug's potential across multiple indications. However, Spark's AI Analyst rates ROIV as Neutral due to ongoing losses and cash burn, despite a strong balance sheet and clinical catalysts. Roivant's current market cap is $20.81 billion, with a year-to-date price performance of 34.98%.

Tip Ranks

Immunovant

Piper Sandler Cos

Top Biotech Insider Makes Bold Multi-Million Dollar Stock Move

Roivant Sciences(ROIV.US)